Robeco Institutional Asset Management B.V. Purchases 86,494 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Robeco Institutional Asset Management B.V. lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 691,607 shares of the medical research company’s stock after buying an additional 86,494 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Thermo Fisher Scientific were worth $344,144,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Cypress Advisory Group LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter worth $253,000. Intact Investment Management Inc. boosted its stake in Thermo Fisher Scientific by 34.0% in the 4th quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company’s stock worth $1,353,000 after purchasing an additional 660 shares during the period. Purkiss Capital Advisors LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter worth $1,121,000. LaFleur & Godfrey LLC boosted its stake in Thermo Fisher Scientific by 9.1% in the 4th quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company’s stock worth $15,486,000 after purchasing an additional 2,488 shares during the period. Finally, Deutsche Bank AG boosted its stake in Thermo Fisher Scientific by 9.5% in the 4th quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company’s stock worth $687,553,000 after purchasing an additional 114,277 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at $9,960,188.31. This represents a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Barclays reduced their target price on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an “equal weight” rating for the company in a research note on Tuesday. Argus reduced their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating for the company in a research note on Tuesday, April 29th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, May 21st. Citigroup reduced their price objective on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Finally, Evercore ISI reduced their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $604.05.

Thermo Fisher Scientific Stock Up 1.5%

Shares of TMO stock opened at $410.45 on Thursday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The firm’s 50-day moving average is $410.39 and its 200-day moving average is $485.33. The stock has a market cap of $154.94 billion, a price-to-earnings ratio of 24.07, a PEG ratio of 2.13 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. Thermo Fisher Scientific’s quarterly revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.11 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.42%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.